Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Jan 18, 2024

Keywords

ClinConnect Summary

The clinical trial titled "Holter of Movement in Patients With Amyotrophic Lateral Sclerosis" is studying how movement in patients with amyotrophic lateral sclerosis (ALS) can be monitored over time. ALS is a progressive disease that affects the nerves and muscles, making it harder for people to move. In this study, researchers want to include about 30 patients who have a confirmed diagnosis of ALS. To be eligible, participants need to be over 18 years old, be stable on their medication (if taking Riluzole), and be able to understand the study tasks.

Participants will visit the study site every three months for a year, where doctors will assess their condition. After each visit, participants will wear a special device called Actimyo for one month, which tracks their movements throughout the day. This study is still looking for volunteers, so if you or someone you know is interested, it’s important to understand the eligibility criteria and that participants should not have significant cognitive issues or recent surgeries that could affect their movement.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
• • Over 18 years old.
• • Signed informed consent
• • If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
• Exclusion Criteria:
• • Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
• • Any other previous or present pathology having an impact on motor function.
• • Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
• • Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
• • Patients participating in an interventional clinical trial.